指南与共识乳腺癌

意大利肿瘤内科协会(AIOM)绝经前激素受体阳性早期乳腺癌辅助内分泌治疗GRADE推荐

Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
指南 / 共识 · Eur J Cancer · 2018-06-07

意大利肿瘤内科协会(AIOM)乳腺癌临床实践指南专家组针对绝经前激素受体阳性早期乳腺癌辅助内分泌治疗的三个关键问题,应用GRADE方法评估证据并形成推荐,以帮助临床医生决策。

要点

  • AIOM指南专家组用GRADE方法评估绝经前激素受体阳性早期乳腺癌辅助内分泌治疗证据。
  • 针对他莫昔芬基础上加卵巢功能抑制(OFS)的作用及激素药物最佳使用等关键问题形成推荐。
  • 推荐旨在帮助临床医生在绝经前乳腺癌患者辅助内分泌治疗中做出决策。

核心结论

  • AIOM指南专家组基于GRADE方法对绝经前激素受体阳性早期乳腺癌辅助内分泌治疗的三个关键问题形成推荐,以辅助临床实践。

研究设计与样本

  • 意大利肿瘤内科协会(AIOM)乳腺癌临床实践指南专家组应用GRADE方法评估证据并制定推荐。

主要发现

  • 专家组针对他莫昔芬基础上加OFS的作用及激素药物最佳使用等三个关键问题总结了现有证据。
  • 多项随机临床试验结果已报道,但绝经前激素受体阳性早期乳腺癌的最佳内分泌治疗算法仍存在开放问题。

关键数值与推荐

  • 绝经前激素受体阳性早期乳腺癌辅助内分泌选项包括他莫昔芬联合或不联合OFS,或芳香化酶抑制剂联合OFS。

临床怎么用

  • 推荐旨在帮助医生在绝经前激素受体阳性早期乳腺癌患者的辅助内分泌治疗中做出临床决策。

局限性

  • 尽管有随机临床试验证据,绝经前激素受体阳性早期乳腺癌的最佳内分泌治疗算法仍存在开放问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Premenopausal women with hormone receptor-positive early breast cancer are candidates for adjuvant endocrine therapy, as recommended by the major international guidelines. To date, adjuvant endocrine options for premenopausal women include tamoxifen with or without ovarian function suppression (OFS) or an aromatase inhibitor with OFS. Multiple strategies for endocrine treatment of premenopausal women with hormone-responsive breast cancer have been assessed, and the results of randomised clinical trials have been reported over the last years. Despite this evidence, the optimal algorithm for endocrine therapy for premenopausal women with hormone receptor-positive early stage invasive breast cancer shows open questions regarding the role of OFS in addition to tamoxifen and the optimal use of hormonal agents. The panel of the Italian Association of Medical Oncology (AIOM) Clinical Practice Guidelines on Breast Cancer applied the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) methodology on three critical questions on the choice of the adjuvant hormonal therapy in premenopausal breast cancer patients to summarise available evidence and to create recommendations to help physicians in their clinical practice.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gori S, Puglisi F, Cinquini M, et al. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). Eur J Cancer. 2018. PMID: 29886394. doi:10.1016/j.ejca.2018.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。